N-of-1 medicine
The fields of precision and personalised medicine have led to promising advances in tailoring treatment to individual patients. Examples include genome/molecular alteration-guided drug selection, single-patient gene therapy design and synergy-based drug combination development, and these approaches...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer – Medknow Publications
2024-03-01
|
| Series: | Singapore Medical Journal |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/singaporemedj.SMJ-2023-243 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823863733069283328 |
|---|---|
| author | Peter Wang Qiao Ying Leong Ni Yin Lau Wei Ying Ng Siong Peng Kwek Lester Tan Shang-Wei Song Kui You Li Ming Chong Isaiah Zhuang Yoong Hun Ong Nigel Foo Xavier Tadeo Kirthika Senthil Kumar Smrithi Vijayakumar Yoann Sapanel Marlena Natalia Raczkowska Alexandria Remus Agata Blasiak Dean Ho |
| author_facet | Peter Wang Qiao Ying Leong Ni Yin Lau Wei Ying Ng Siong Peng Kwek Lester Tan Shang-Wei Song Kui You Li Ming Chong Isaiah Zhuang Yoong Hun Ong Nigel Foo Xavier Tadeo Kirthika Senthil Kumar Smrithi Vijayakumar Yoann Sapanel Marlena Natalia Raczkowska Alexandria Remus Agata Blasiak Dean Ho |
| author_sort | Peter Wang |
| collection | DOAJ |
| description | The fields of precision and personalised medicine have led to promising advances in tailoring treatment to individual patients. Examples include genome/molecular alteration-guided drug selection, single-patient gene therapy design and synergy-based drug combination development, and these approaches can yield substantially diverse recommendations. Therefore, it is important to define each domain and delineate their commonalities and differences in an effort to develop novel clinical trial designs, streamline workflow development, rethink regulatory considerations, create value in healthcare and economics assessments, and other factors. These and other segments are essential to recognise the diversity within these domains to accelerate their respective workflows towards practice-changing healthcare. To emphasise these points, this article elaborates on the concept of digital health and digital medicine-enabled N-of-1 medicine, which individualises combination regimen and dosing using a patient’s own data. We will conclude with recommendations for consideration when developing novel workflows based on emerging digital-based platforms. |
| format | Article |
| id | doaj-art-031ae48a3c1a4d3ba72da490081bbc41 |
| institution | Kabale University |
| issn | 0037-5675 2737-5935 |
| language | English |
| publishDate | 2024-03-01 |
| publisher | Wolters Kluwer – Medknow Publications |
| record_format | Article |
| series | Singapore Medical Journal |
| spelling | doaj-art-031ae48a3c1a4d3ba72da490081bbc412025-02-09T10:19:44ZengWolters Kluwer – Medknow PublicationsSingapore Medical Journal0037-56752737-59352024-03-0165316717510.4103/singaporemedj.SMJ-2023-243N-of-1 medicinePeter WangQiao Ying LeongNi Yin LauWei Ying NgSiong Peng KwekLester TanShang-Wei SongKui YouLi Ming ChongIsaiah ZhuangYoong Hun OngNigel FooXavier TadeoKirthika Senthil KumarSmrithi VijayakumarYoann SapanelMarlena Natalia RaczkowskaAlexandria RemusAgata BlasiakDean HoThe fields of precision and personalised medicine have led to promising advances in tailoring treatment to individual patients. Examples include genome/molecular alteration-guided drug selection, single-patient gene therapy design and synergy-based drug combination development, and these approaches can yield substantially diverse recommendations. Therefore, it is important to define each domain and delineate their commonalities and differences in an effort to develop novel clinical trial designs, streamline workflow development, rethink regulatory considerations, create value in healthcare and economics assessments, and other factors. These and other segments are essential to recognise the diversity within these domains to accelerate their respective workflows towards practice-changing healthcare. To emphasise these points, this article elaborates on the concept of digital health and digital medicine-enabled N-of-1 medicine, which individualises combination regimen and dosing using a patient’s own data. We will conclude with recommendations for consideration when developing novel workflows based on emerging digital-based platforms.https://journals.lww.com/10.4103/singaporemedj.SMJ-2023-243digital healthdigital medicinen-of-1personalised medicine |
| spellingShingle | Peter Wang Qiao Ying Leong Ni Yin Lau Wei Ying Ng Siong Peng Kwek Lester Tan Shang-Wei Song Kui You Li Ming Chong Isaiah Zhuang Yoong Hun Ong Nigel Foo Xavier Tadeo Kirthika Senthil Kumar Smrithi Vijayakumar Yoann Sapanel Marlena Natalia Raczkowska Alexandria Remus Agata Blasiak Dean Ho N-of-1 medicine Singapore Medical Journal digital health digital medicine n-of-1 personalised medicine |
| title | N-of-1 medicine |
| title_full | N-of-1 medicine |
| title_fullStr | N-of-1 medicine |
| title_full_unstemmed | N-of-1 medicine |
| title_short | N-of-1 medicine |
| title_sort | n of 1 medicine |
| topic | digital health digital medicine n-of-1 personalised medicine |
| url | https://journals.lww.com/10.4103/singaporemedj.SMJ-2023-243 |
| work_keys_str_mv | AT peterwang nof1medicine AT qiaoyingleong nof1medicine AT niyinlau nof1medicine AT weiyingng nof1medicine AT siongpengkwek nof1medicine AT lestertan nof1medicine AT shangweisong nof1medicine AT kuiyou nof1medicine AT limingchong nof1medicine AT isaiahzhuang nof1medicine AT yoonghunong nof1medicine AT nigelfoo nof1medicine AT xaviertadeo nof1medicine AT kirthikasenthilkumar nof1medicine AT smrithivijayakumar nof1medicine AT yoannsapanel nof1medicine AT marlenanataliaraczkowska nof1medicine AT alexandriaremus nof1medicine AT agatablasiak nof1medicine AT deanho nof1medicine |